THE FINANCIAL — Nestlé announced today the successful completion of its acquisition of Aimmune Therapeutics, Inc. (Nasdaq: AIMT). Joining Nestlé Health Science (NHSc) as a stand-alone business unit called Aimmune Therapeutics, a Nestlé Health Science company, it will manage NHSc‘s global pharmaceutical business.
More
The FINANCIAL — Société des Produits Nestlé S.A. (“Nestlé”) today announced the results of the tender offer by its wholly-owned subsidiary, SPN MergerSub, Inc. (“Purchaser”), to purchase all of the outstanding shares (“Shares”) of common stock of Aimmune Therapeutics, Inc. (Nasdaq: AIMT)
More
The FINANCIAL — Nestle agreed to buy Aimmune Therapeutics Inc. for $2.6 billion, adding a promising peanut allergy treatment to its portfolio of coffee, snacks and water. The Swiss owner of Nespresso will pay $34.50 a share for the U.S. biotech firm, almost
More